Loading
Loading
Research Overview
Synthetic somatostatin octapeptide analogue; binds SSTR2 and SSTR5 receptors on pituitary somatotrophs and neuroendocrine cells to suppress GH release, glucagon, insulin, and gut hormone secretion — the mechanistic inverse of GH secretagogues.
Overview
Octreotide is a stable synthetic octapeptide analogue of somatostatin — the endogenous hormone that inhibits GH, glucagon, insulin, and various gut hormones. By binding SSTR2 and SSTR5 receptors preferentially, octreotide mimics somatostatin's inhibitory effects on the pituitary and pancreatic cells responsible for GH and gut hormone excess in disease states.
In acromegaly (GH excess from pituitary adenoma), octreotide suppresses GH and IGF-1 levels to near-normal ranges in approximately 60–70% of patients, reducing symptoms of growth hormone excess. In carcinoid syndrome and VIPomas, it suppresses the tumour-derived hormone overproduction causing flushing, diarrhoea, and other endocrine symptoms.
Octreotide is available in immediate-release (subcutaneous three times daily) and long-acting depot (intramuscular monthly) formulations. As an FDA-approved prescription medicine, it is obtained through specialist prescribers rather than research supply chains. Its mention in research contexts is primarily educational and comparative — understanding how somatostatin agonism contrasts with GH secretagogue mechanisms.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, octreotide (sandostatin) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Synthetic somatostatin octapeptide analogue; binds SSTR2 and SSTR5 receptors on pituitary somatotrophs and neuroendocrine cells to suppress GH release, glucagon, insulin, and gut hormone secretion — the mechanistic inverse of GH secretagogues.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.